FDA OKs Glenmark’s generic Protopic Ointment
Glenmark Pharmaceuticals’ generic Protopic Ointment (tacrolimus ointment, 0.1% has received approval from the Food and Drug Administration. The drug is indicated to treat moderate-to-severe atopic dermatitis in adults who haven’t responded adequately to other topical treatments.
The product — including branded and generic Protopic Ointment — had a U.S. market size of roughly $109 million for the 12 months ended February 2018, according to IQVIA data.
The product — including branded and generic Protopic Ointment — had a U.S. market size of roughly $109 million for the 12 months ended February 2018, according to IQVIA data.